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An emerging role for agmatine. Polyamines, required compo- thesis and to transport in an antizyme-dependent fashion
nents of proliferation, are autoregulated by the protein anti- [15]. The induction of antizyme was previously thought
zyme. To date, agmatine is the only molecule other than the to be exclusively in response to intracellular polyaminepolyamines that can induce antizyme, and thus influence cell
levels. Agmatine is the only known molecule to date,homeostasis and growth. Agmatine has effectively suppressed
exclusive of the canonical polyamines, with the capacityproliferation in immortalized and transformed cell lines. An
increased sensitivity to the anti-proliferative effects of agmatine to induce antizyme. Agmatine has been previously de-
observed in Ras transformed versus native cells paralleled an scribed to interact with a number of receptors [16–19],
increase in agmatine uptake in the transformed cells. We hy- and many effects were proposed to be receptor depen-pothesize that agmatine may target transformed cells via selec-
dent. The induction of antizyme by agmatine, however,tive transporters.
was shown to be receptor independent [15]. In accord
with the observation of antizyme induction, agmatine ad-
ministration markedly reduced intracellular polyaminePolyamines (putrescine, spermidine, and spermine)
levels and cellular proliferation in a transformed proxi-are small ubiquitous cationic molecules required for cell
mal tubule cell line, suggesting a role for agmatine as ahomeostasis and growth [1, 2]. Polyamine biosynthesis
tumor suppressor [15].is regulated throughout the cell cycle, resulting in aug-
Although ADC activity is most prevalent in the kidneymented intracellular polyamine levels [3]. As such, poly-
and the liver [20, 21], agmatine is distributed by theamines have been described to play an important role
plasma and has been shown to be selectively concen-in the transformation process [4–8]. Conversely, the
trated in several organs [20, 22]. We have found, in fact,depletion of intracellular polyamines results in the sup-
that agmatine was effective at suppressing ODC activitypression of growth [9, 10]. In spite of the need for poly-
in all immortalized and transformed cell lines examinedamines for cell cycle progression, their specific regulatory
[15]. To begin to explore the possibility that agmatineroles in this capacity have yet to be fully resolved.
is selectively targeted to rapidly proliferating and/orIntracellular polyamine concentrations are autoregu-
transformed cells, we used the fibroblast-like NIH 3T3lated by the induction of the protein antizyme [11]. Anti-
cell line and a more rapidly growing Ras-transformedzyme is the only known endogenous protein that binds to
NIH 3T3 variant (Ras-3T3) as a model system. We ob-the first rate-limiting enzyme of polyamine biosynthesis,
served that the uptake of agmatine by the Ras-3T3 cellornithine decarboxylase (ODC), inhibiting its activity
line was higher than in the native NIH 3T3 cells. Thisand accelerating its degradation [12]. In addition to in-
increased transport capacity for agmatine by Ras-3T3hibiting polyamine biosynthesis, antizyme has been
cells was reflected in their increased sensitivity, overshown to concurrently suppress polyamine transporters
NIH3T3 cells, to agmatine-mediated suppression of pro-[13, 14]. Because of this unique, two-pronged negative
liferation and cell cycle effects (manuscript in prepara-feedback system, antizyme is an effective endogenous
tion).protein in limiting intracellular polyamine levels.
Agmatine depletion of polyamines can inhibit cellAgmatine is a metabolite of arginine via arginine de-
growth [15]. The extent of this effect on proliferationcarboxylase (ADC), an arginine pathway distinct from
may be limited to the cell’s ability to incorporate agma-that of the polyamines. We have recently demonstrated
tine. We hypothesize that agmatine may be selectivelythe capacity of agmatine to suppress polyamine biosyn-
targeted to more rapidly proliferating cells, which would
further support agmatine as a potential endogenous tu-
mor suppressor. Defining an agmatine transport systemKey words: arginine decarboxylase, polyamines, cell homeostasis.
An emerging role for agmatine is an important aspect of this hypothesis and is currently
under investigation. 1999 by the International Society of Nephrology
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